Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 34 and last traded at GBX 35, with a volume of 48944 shares traded. The stock had previously closed at GBX 35.
Faron Pharmaceuticals Oy Price Performance
The firm has a market capitalization of £71.01 million, a P/E ratio of -3.04 and a beta of 1.12. The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 154.15. The business’s 50 day moving average is GBX 39.74 and its 200-day moving average is GBX 42.97.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Recommended Stories
- Five stocks we like better than Faron Pharmaceuticals Oy
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
- Apple Is Quietly Building an AI Advantage Few Expected
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
